# Yakult 

# Supplementary Materials for Financial Statements for The Third Quarter Ended December 31, 2011 (April 1, 2011 to December 31, 2011) 

January 31, 2012
Yakult Honsha Co., Ltd.
Public Relations Department Investor Relations Department URL http://ir.yakult.co.jp/

## Contents

## Consolidated

1.Major Increases (Decreases) in Consolidated Balance Sheets
2. Major Increases (Decreases) in Consolidated Statements of Income ..... $\cdot 2$
3. Performance Overview ..... - 3
4. Segment Information ..... 4-6
5. Overseas companies Dairy Products sales( Bottles sold per day ) ..... 7
(Reference ) Non-Consolidated

1. Breakdown of Statements of Income ..... 8
2. Sales breakdown ..... 8-10
[^0]
## Consolidated

## 1. Major Increases (Decreases) in Consolidated Balance Sheets

|  | $\begin{gathered} \text { As of Mar.31. } \\ 2011 \end{gathered}$ | $\begin{gathered} \text { As of Dec. } 31 . \\ 2011 \end{gathered}$ | Increase <br> (Decrease) |
| :---: | :---: | :---: | :---: |
| Total Assets | 392,828 | 395,479 | 2,651 |
| Current assets <br> Cash and deposits <br> Notes and accounts receivable <br> Inventories <br> Others | $\begin{aligned} & 88,837 \\ & 49,073 \\ & 27,740 \\ & 17,179 \end{aligned}$ | $\begin{aligned} & 84,267 \\ & 55,730 \\ & 30,241 \\ & 15,477 \end{aligned}$ | $\begin{gathered} (4,569) \\ 6,657 \\ 2,501 \\ (1,701) \end{gathered}$ |
| Fixed assets <br> Tangible fixed assets Buildings and structures Others | $\begin{aligned} & 47,692 \\ & 86,025 \end{aligned}$ | $\begin{aligned} & 47,410 \\ & 87,064 \end{aligned}$ | $\begin{gathered} (281) \\ 1,039 \end{gathered}$ |
| Intangible fixed assets | 5,911 | 5,861 | (49) |
| Investments and other assets Investment securities <br> Others | $\begin{aligned} & 57,288 \\ & 13,080 \end{aligned}$ | $\begin{aligned} & 56,489 \\ & 12,935 \end{aligned}$ | $\begin{aligned} & (799) \\ & (144) \end{aligned}$ |
| Total Liabilities | 141,856 | 146,003 | 4,147 |
| Current liabilities <br> Notes and accounts payable <br> Short-term loans <br> Allowance for loss on disaster <br> Others | $\begin{array}{r} 22,167 \\ 3,466 \\ 712 \\ 36,828 \end{array}$ | $\begin{array}{r} 26,452 \\ 9,923 \\ 33,568 \end{array}$ | $\begin{array}{r} 4,284 \\ 6,456 \\ (712) \\ (3,260) \end{array}$ |
| Fixed liabilities <br> Long-term loans <br> Allowance for retirement benefits <br> Others | $\begin{aligned} & 42,951 \\ & 18,855 \\ & 16,874 \end{aligned}$ | $\begin{aligned} & 42,473 \\ & 18,129 \\ & 15,456 \end{aligned}$ | $\begin{array}{r} (477) \\ (726) \\ (1,417) \end{array}$ |
| Total Net Assets | 250,971 | 249,475 | $(1,495)$ |
| Shareholder's Equity <br> Accumulated other comprehensive income <br> Minority Interests | $\begin{array}{r} \hline 264,256 \\ (38,369) \\ 25,085 \end{array}$ | $\begin{array}{r} \hline 273,524 \\ (48,624) \\ 24,575 \end{array}$ | $\begin{array}{r} 9,268 \\ (10,254) \\ (509) \end{array}$ |

## 2．Major Increases（Decreases）in Consolidated Statements of Income

（Millions of yen）

|  | 3Q of FY 2011 <br> （April 1，2010～ December 31，2010） | 3Q of FY 2012 <br> （April 1，2011～ <br> December 31，2011） | Increase（Decrease） |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  |  | Amount | Ratio（\％） |
| Net sales | 236，396 | 239，978 | 3，581 | 1．5 |
| （Sales by business segments） <br> Food and beverages（Japan） <br> Food and beverages（Overseas） <br> Pharmaceuticals <br> Others <br> Adjustments | $\begin{array}{r} 146,554 \\ 54,095 \\ 30,114 \\ 14,217 \\ (8,584) \\ \hline \end{array}$ | $\begin{array}{r} 144,107 \\ 60,178 \\ 30,186 \\ 14,820 \\ (9,314) \\ \hline \end{array}$ | $\begin{gathered} (2,447) \\ 6,083 \\ 72 \\ 603 \\ (730) \\ \hline \end{gathered}$ | $\begin{array}{r} (1.7) \\ 11.2 \\ 0.2 \\ 4.2 \end{array}$ |
| Cost of sales | 106，413 | 109，398 | 2，984 | 2.8 |
| Gross profit <br> Gross profit margin（\％） | $\begin{array}{r} 129,983 \\ 55.0 \\ \hline \end{array}$ | $\begin{array}{r} \hline 130,579 \\ 54.4 \end{array}$ | 596 | 0.5 |
| Selling，general and administrative expenses <br> Selling expenses <br> General and administrative expenses | $\begin{array}{r} \hline 110,423 \\ 50,086 \\ 60,337 \\ \hline \end{array}$ | $\begin{array}{r} \hline 111,464 \\ 49,312 \\ 62,151 \\ \hline \end{array}$ | $\begin{gathered} \hline 1,040 \\ (773) \\ 1,814 \\ \hline \end{gathered}$ | 0.9 |
| Operating income <br> Operating income margin（\％） | $\begin{array}{r} \hline \mathbf{1 9 , 5 5 9} \\ 8.3 \\ \hline \end{array}$ | $\begin{array}{r} \hline 19,115 \\ 8.0 \end{array}$ | （444） | （2．3） |
| （Operating income by business segments） <br> Food and beverages（Japan） <br> Food and beverages（Overseas） <br> Pharmaceuticals <br> Others <br> Adjustments <br> 【Corporate expenses】 | 9,288 <br> 10,507 <br> 9,606 <br> 89 <br> $(9,932)$ <br> $\lfloor(8,762) 】$ | 9,051 11,737 8,192 921 $(10,788)$ $\lfloor(9,404) 】$ |  | $\begin{array}{r} (2.5) \\ 11.7 \\ (14.7) \\ - \\ - \end{array}$ |
| Non－operating income <br> Interests <br> Dividends <br> Investment gains on the equity method <br> Others <br> Non－operating expenses <br> Interest <br> Others | $\begin{array}{r} 5,934 \\ 1,372 \\ 557 \\ 2,523 \\ 1,480 \\ 1,192 \\ 616 \\ 575 \\ \hline \end{array}$ | 7,242 1,817 586 2,402 2,436 1,060 504 556 | $\begin{gathered} 1,307 \\ 444 \\ 28 \\ (121) \\ 955 \\ (131) \\ (112) \\ (18) \\ \hline \end{gathered}$ | 22.0 (11.0) |
| Ordinary income <br> Ordinary income margin（\％） | $\begin{array}{r} 24,302 \\ 10.3 \\ \hline \end{array}$ | $\begin{array}{r} \hline 25,296 \\ 10.5 \\ \hline \end{array}$ | 994 | 4.1 |
| Extraordinary gain <br> Extraordinary loss | $\begin{array}{r} 421 \\ 2,040 \\ \hline \end{array}$ | $\begin{aligned} & \hline 2,243 \\ & 3,582 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,822 \\ & 1,541 \end{aligned}$ | 75.5 |
| Income before income taxes and minority interests | 22，682 | 23，957 | 1，274 | 5.6 |
| Income taxes <br> Minority interests | $\begin{aligned} & \hline 6,789 \\ & 2,283 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 7,463 \\ & 3,367 \\ & \hline \end{aligned}$ | $\begin{array}{r} 674 \\ 1,083 \\ \hline \end{array}$ |  |
| Net income $\quad$ Net income margin（\％） | $\begin{array}{r} 13,609 \\ 5.8 \\ \hline \end{array}$ | $\begin{array}{r} 13,126 \\ 5.5 \end{array}$ | （483） | （3．6） |

## 3. Performance Overview

(1) Breakdown of Statements of Income
(Millions of yen)

(2) Breakdown of Gains on Equity Method
(Millions of yen)

|  | $\begin{gathered} \text { 3Q of FY } 2011 \\ \text { (April 1, } 2010 \sim \text { December 31, 2010) } \end{gathered}$ |  | 3Q of FY 2012 <br> (April 1, 2011 ~ December 31, 2011) |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Results | Year on year(\%) | Results | Year on year(\%) |
| Gain on Equity Method | 2,523 | 128.4 | 2,402 | 95.2 |

## 4.Segment Information

## (1) Actual Results

(1) Result of the third quarter ended December 31, 2010 (April 1, 2010 ~ December 31, 2010)
(Millions of yen)

|  | Food and beverages |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: |
|  | Japan | Overseas Total | The Americas | Asia and Oceania | Europe |
| Net sales | 146,554 | 54,095 | 28,390 | 19,231 | 6,473 |
| Percentage of net sales | 62.0 | 22.9 | 12.0 | 8.1 | 2.8 |
| Year on year | 107.0 | 108.2 | 111.0 | 112.2 | 89.2 |
| Operating expenses | 137,266 | 43,587 | 21,846 | 15,923 | 5,817 |
| Year on year | 107.2 | 109.1 | 112.6 | 116.7 | 84.3 |
| Operating income (loss) | 9,288 | 10,507 | 6,544 | 3,307 | 655 |
| Year on year | 104.3 | 104.7 | 105.9 | 94.5 | 182.8 |
| Operating income margin | 6.3 | 19.4 | 23.1 | 17.2 | 10.1 |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | 30,114 | 14,217 | 244,981 |  | 236,396 |
| Percentage of net sales | 12.7 | 6.0 | 103.6 | $(3.6)$ | 100.0 |
| Year on year | 112.1 | 119.2 | 108.5 | --- | 106.6 |
| Operating expenses | 20,507 | 14,127 | 215,488 | 1,348 | 216,836 |
| Year on year | 117.3 | 123.5 | 109.4 | 24.0 | 107.1 |
| Operating income (loss) | 9,606 | 89 | 29,492 | * $(9,932)$ | 19,559 |
| Year on year | 102.4 | 18.3 | 102.4 | --- | 101.6 |
| Operating income margin | 31.9 | 0.6 | --- | --- | 8.3 |

※Adjustment $\cdots 9,932$ million yen of adjustment include 8,762 million yen of administrative expenses in parent company.
Also note that the difference amount of 1,170 million yen is elimination of royalty income.
(2)Result of the third quarter ended December 31, 2011 (April 1, 2011 ~ December 31, 2011)

|  | (Millions of yen) |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Food and beverages |  |  |  |  |
|  | Japan | Overseas Total | The Americas | Asia and Oceania | Europe |
| Net sales | 144,107 | 60,178 | 30,198 | 23,874 | 6,106 |
| Percentage of net sales | 60.1 | 25.0 | 12.6 | 9.9 | 2.5 |
| Year on year | 98.3 | 111.2 | 106.4 | 124.1 | 94.3 |
| Operating expenses | 135,055 | 48,440 | 23,038 | 19,336 | 6,065 |
| Year on year | 98.4 | 111.1 | 105.5 | 121.4 | 104.3 |
| Operating income (loss) | 9,051 | 11,737 | 7,159 | 4,537 | 40 |
| Year on year | 97.5 | 111.7 | 109.4 | 137.2 | 6.2 |
| Operating income margin | 6.3 | 19.5 | 23.7 | 19.0 | 0.7 |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 30,186 | 14,820 | 249,292 | $(9,314)$ | 239,978 |
| Percentage of net sales | 12.6 | 6.2 | 103.9 | (3.9) | 100.0 |
| Year on year | 100.2 | 104.2 | 101.8 | 108.5 | 101.5 |
| Operating expenses | 21,993 | 13,898 | 219,388 | 1,474 | 220,862 |
| Year on year | 107.3 | 98.4 | 101.8 | 109.3 | 101.9 |
| Operating income (loss) | 8,192 | 921 | 29,904 | ※ (10,788) | 19,115 |
| Year on year | 85.3 | --- | 101.4 | 108.6 | 97.7 |
| Operating income margin | 27.1 | 6.2 | --- | --- | 8.0 |

[^1]
## 〈Reference〉

Result of the third quarter ended December 31, 2011.
(Jan. - Sep. (using exchange rate of the average 2010))
(3)Result of the third quarter ended December 31, 2011(April 1, 2011 ~ December 31, 2011)

|  | (Millions of yen) |  |  |  |  |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Japan |  |  |  |  |  | Overseas Total |  | The Americas | Asia and Oceania | Europe |
| Net sales | 144,107 | 62,845 | 31,421 | 25,103 | 6,319 |  |  |  |  |  |  |
| Percentage of net sales | 59.4 | 25.9 | 13.0 | 10.3 | 2.6 |  |  |  |  |  |  |
| Year on year | 98.3 | 116.2 | 110.7 | 130.5 | 97.6 |  |  |  |  |  |  |
| Operating expenses | 135,055 | 50,656 | 23,967 | 20,431 | 6,256 |  |  |  |  |  |  |
| Year on year | 98.4 | 116.2 | 109.7 | 128.3 | 107.5 |  |  |  |  |  |  |
| Operating income (loss) | 9,051 | 12,189 | 7,454 | 4,671 | 63 |  |  |  |  |  |  |
| Year on year | 97.5 | 116.0 | 113.9 | 141.2 | 9.6 |  |  |  |  |  |  |
| Operating income margin | 6.3 | 19.4 | 23.7 | 18.6 | 1.0 |  |  |  |  |  |  |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | 30,186 | 14,820 | 251,958 |  | 242,644 |
| Percentage of net sales | 12.4 | 6.1 | 103.8 | $(3.8)$ | 100.0 |
| Year on year | 100.2 | 104.2 | 102.8 | 108.5 | 102.6 |
| Operating expenses | 21,993 | 13,898 | 221,603 | 1,474 | 223,077 |
| Year on year | 107.3 | 98.4 | 102.8 | 109.3 | 102.9 |
| Operating income (loss) | 8,192 | 921 | 30,355 | $\times(10,788)$ | 19,566 |
| Year on year | 85.3 | --- | 102.9 | 108.6 | 100.0 |
| Operating income margin | 27.1 | 6.2 | --- | --- | 8.1 |

※Adjustment $\cdots 10,788$ million yen of adjustment include 9,404 million yen of administrative expenses in parent company.
Also note that the difference amount of 1,384 million yen is elimination of royalty income.
5. Overseas companies Dairy Products sales( Bottles sold per day )
(Unit:Thousands of bottles/day. \%)

|  | Consolidation Classification | 3Q of FY 2012 <br> (From January to September, 2011.) |  | Preliminary figure <br> (From January to December, 2011.) |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Sales quantity | Year on year | Sales quantity | Year on year |
| Taiwan | Equity method | 907 | 102.8 | 890 | 103.9 |
| Hong Kong $\quad{ }_{1}$ | Consolidated | 477 | 112.7 | 481 | 115.4 |
| Thailand $\quad$ ※2 | Equity method | 2,685 | 105.4 | 2,234 | 86.2 |
| Korea | Equity method | 4,104 | 99.4 | 4,001 | 98.8 |
| Philippines | Equity method | 1,246 | 99.1 | 1,295 | 106.2 |
| Singapore | Consolidated | 197 | 102.7 | 194 | 101.7 |
| Indonesia | Consolidated | 2,246 | 131.1 | 2,253 | 127.5 |
| Australia | Consolidated | 208 | 112.2 | 207 | 110.5 |
| Malaysia | Consolidated | 190 | 116.9 | 194 | 119.7 |
| Vietnam $\quad$ 3 | Consolidated | 62 | 161.6 | 68 | 172.3 |
| India $\quad{ }_{4}$ | Consolidated | 46 | 162.7 | 48 | 162.6 |
| Guangzhou | Consolidated | 1,213 | 132.9 | 1,235 | 136.7 |
| Shanghai | Consolidated | 308 | 126.0 | 311 | 127.6 |
| Beijing | Consolidated | 169 | 127.9 | 167 | 129.5 |
| China $\quad$ * | Consolidated | 598 | 171.3 | 595 | 170.5 |
| China total |  | 2,288 | 139.6 | 2,309 | 142.0 |
| Asia and Oceania total <br> (Consolidated subsidiary company Total) |  | 14,656 <br> 5,713 | $\begin{aligned} & 111.1 \\ & 130.4 \end{aligned}$ | $\begin{array}{r} 14,174 \\ 5,755 \end{array}$ | $\begin{aligned} & 107.9 \\ & 130.2 \end{aligned}$ |
| Brazil | Consolidated | 1,687 | 108.4 | 1,706 | 108.4 |
| Mexico | Consolidated | 3,381 | 105.4 | 3,309 | 104.1 |
| Argentina | Consolidated | 20 | 72.4 | 20 | 77.2 |
| USA | Consolidated | 122 | 113.4 | 125 | 116.8 |
| The Americas total |  | 5,210 | 106.4 | 5,160 | 105.7 |
| Netherlands | Consolidated | 220 | 103.0 | 220 | 102.0 |
| Belgium | Consolidated | 76 | 95.3 | 76 | 94.8 |
| United Kingdom | Consolidated | 206 | 91.3 | 203 | 89.9 |
| Germany | Consolidated | 108 | 92.1 | 105 | 88.3 |
| Austria | Consolidated | 18 | 80.8 | 17 | 85.2 |
| Italy | Consolidated | 58 | 146.1 | 64 | 146.9 |
| Europe total |  | 687 | 98.3 | 686 | 97.3 |
| Total <br> (Consolidated subsidiary company Total) |  | $\begin{aligned} & 20,553 \\ & 11,609 \end{aligned}$ | $\begin{aligned} & 109.4 \\ & 116.4 \end{aligned}$ | $\begin{aligned} & 20,021 \\ & 11,602 \end{aligned}$ | 106.9 115.9 |

[^2]
## (Reference ) Non-Consolidated

Non-consolidated financial results are presented in accordance with "Regulation for quarterly financial statements".
But, it is not subject to be reviewed by auditors under the law.

## 1. Breakdown of Statements of Income

(Millions of yen \%)

|  | $\begin{gathered} \text { 3Q of FY } 2011 \\ \text { (April 1, } 2010 \sim \text { December 31, 2010) } \end{gathered}$ |  | 3Q of FY 2012$\text { (April 1, } 2011 \text { ~ December 31, 2011) }$ |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Results | Year on year(\%) | Results | Year on year(\%) |
| Net sales | 136,501 | 107.6 | 134,708 | 98.7 |
| Operating income | 7,929 | 109.3 | 6,469 | 81.6 |
| Ordinary income | 9,805 | 92.1 | 8,786 | 89.6 |
| Net income | 6,268 | 114.3 | 3,608 | 57.6 |

## 2. Sales breakdown

(1) Sales by Product Category

|  | 3Q of FY 2011 <br> (April 1, 2010 ~ December 31, 2010) |  | $\begin{gathered} \text { 3Q of FY } 2012 \\ \text { (April 1, } 2011 \sim \text { December 31, 2011) } \end{gathered}$ |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Results | Year on year(\%) | Results | Year on year(\%) |
| Dairy products | 60,140 | 104.5 | 57,502 | 95.6 |
| Juices and other beverages etc. | 29,535 | 104.8 | 29,725 | 100.6 |
| Subtotal | 89,676 | 104.6 | 87,227 | 97.3 |
| Cosmetics | 5,043 | 100.1 | 5,182 | 102.8 |
| Pharmaceuticals | 30,114 | 112.1 | 30,186 | 100.2 |
| Others | 11,667 | 127.1 | 12,112 | 103.8 |
| Total | 136,501 | 107.6 | 134,708 | 98.7 |

Note) Sales amounts of health foods and noodles that had been included in "Others" were presented in
"Juices and other beverages etc." starting from FY2011.
(2) Dairy Products sales (Bottles sold per day)

|  |  |  | 3Q of FY 2011 <br> (April 1, 2010 ~ December 31, 2010) |  | $\begin{gathered} \text { 3Q of FY } 2012 \\ \text { (April 1, } 2011 \sim \text { December 31, 2011) } \end{gathered}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Results | Year on year(\%) | Results | Year on year(\%) |
|  | Yakult |  | 3,178 | 98.6 | 3,241 | 102.0 |
|  | Yakult Calorie Half | ※3 | 145 | 125.1 | 90 | 62.5 |
|  | Yakult 300V | ※3 | 147 | 92.3 | 68 | 46.0 |
|  | Yakult SHEs | ※3 | 64 | 96.2 | 26 | 40.3 |
|  | Yakult SHEs hard type | ※2 | 16 | 279.7 | --- | --- |
|  | Yakult 400 products total |  | 3,037 | 100.4 | 3,121 | 102.8 |
|  | Yakult 400 |  | 1,330 | 86.7 | 1,204 | 90.6 |
|  | Yakult 400LT |  | 1,707 | 114.5 | 1,917 | 112.3 |
|  | Yakult products total |  | 6,587 | 99.7 | 6,546 | 99.4 |
|  | BF-1 |  | 116 | 106.8 | 102 | 88.4 |
|  | Pretio |  | 146 | 83.2 | 127 | 86.9 |
|  | Joie |  | 711 | 102.7 | 730 | 102.6 |
|  | Mil-Mil | ※1 | 518 | --- | 566 | 109.3 |
|  | Bifiene products | * | 174 | 47.5 | --- | --- |
|  | Sofuhl |  | 507 | 96.1 | 427 | 84.3 |
|  | Purela |  | 152 | 91.1 | 182 | 119.9 |
|  | Yakult Genki Yogurt | ※3 | 19 | --- | 9 | 49.4 |
|  | Fermented milk total |  | 2,081 | 117.7 | 1,914 | 92.0 |
|  | Total |  | 8,929 | 102.9 | 8,689 | 97.3 |

※1 Mil-Mil S (Launch on Oct.4, 2010)
※2 Yakult SHEs hard type (Temporal stop of sales)
※3 Temporal stop of sales according to the Great East Japan Earthquake (until end of June)

* Stop sales


## (3) Juices and Other Beverages sales ( Total Bottles sold)

(Thousands of bottles. \%)

|  |  | $\begin{gathered} \text { 3Q of FY } 2011 \\ \text { (April 1, } 2010 \sim \text { December 31, 2010) } \end{gathered}$ |  | 3Q of FY 2012(April 1, 2011~ December 31, 2011) |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Results | Year on year(\%) | Results | Year on year(\%) |
|  | Bansoreicha | 31,152 | 91.5 | 26,972 | 86.6 |
|  | Toughman ※ | 47,978 | 100.6 | 55,228 | 115.1 |
|  | Kurozu Drink | 42,571 | 101.2 | 37,977 | 89.2 |
|  | Soy milk drinks | 30,336 | 96.6 | 33,378 | 110.0 |
|  | Lemorea | 9,987 | 77.9 | 6,831 | 68.4 |
|  | Milougu | 22,912 | 99.6 | 30,222 | 131.9 |
|  | Juices | 51,402 | 117.1 | 53,577 | 104.2 |
|  | Kininaruyasai | 46,502 | 100.6 | 48,127 | 103.5 |
|  | Coffee Time | 27,836 | 89.7 | 27,140 | 97.5 |
|  | FIRE | 57,372 | 97.7 | 59,744 | 104.1 |
|  | Coffee products total | 85,208 | 94.9 | 86,884 | 102.0 |
|  | Gogono-kocha | 23,911 | 135.8 | 25,724 | 107.6 |

※ Toughmansuper (Launch on Oct.10, 2011)
(4)Pharmaceuticals sales
(Millions of yen \%)


## CAUTIONARY STATEMENT

Statements contained in these materials with respect to Yakult's plans, forecasts and other statements that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ substantially from expectations.
The information contained in these materials is not intended as a solicitation for investment. Furthermore, Yakult does not guarantee the accuracy of the contents of these materials. Yakult and the provider of these materials disclaim any responsibility for any loss or damage that should arise from the use of this information.


[^0]:    About a numeric display of this material
    1.Unit of money : Less than one million yen is rounded down.
    2. Quantity results: Less than 1,000 is rounded off.
    3.Year on year percentage: The second place is rounded off after the decimal point.

[^1]:    ※Adjustment $\cdots 10,788$ million yen of adjustment include 9,404 million yen of administrative expenses in parent company.
    Also note that the difference amount of 1,384 million yen is elimination of royalty income.

[^2]:    <Accounting period: From January to December>
    ※1:Hong Kong: Yakult LT (Started sales from 18 May. 2011)
    ※2:Thailand : Accounting date:31 May. Bangkok factory and Ayutthaya factory stopped operation for about 2months since October. 2011 due to severe floods. (Bangkok factory started delivery from 16 December. 2011 and Ayutthaya factory from 22 December. 2011.)
    ※3:Vietnam:Hanoi City (Started sales from 16 May. 2011)
    ※4:India: Accounting date: 31 Mar.
    $※ 5$ : (1)Sales Area of Yakult (China) : Tianjin city, Suzhou city, Hangzhou city, Qingdao city, Nanjing city, Ningbo city, Jinan city, Yantai city, Wuhan city, Wenzhou city, Shenyang city, Xiamen city, Dalian city, Fuzhou city, Hefei city and neighboring cities, excluding Guangdong, Hainan, Shanghai city and Beijing city.
    (2)Tianjin Yakult : Delivers products to Yakult (China) (Started manufacturing from 3 Aug. 2011)

